- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07916051
Esketamine Combined With Transcutaneous Electrical Acupoint Stimulation on Postoperative Recovery Quality After Elective Cesarean Section
Effects of Esketamine Combined With Transcutaneous Electrical Acupoint Stimulation on Postoperative Recovery Quality in Parturients Undergoing Cesarean Section: a Prospective Randomized Controlled Trial
This study is a prospective randomized controlled trial aimed at evaluating whether the combination of esketamine and transcutaneous electrical acupoint stimulation (TEAS) can improve the quality of postoperative recovery in women undergoing elective cesarean section. First-time mothers scheduled for surgery will be randomly assigned to one of four groups: a control group (standard care), a TEAS group, an esketamine group, or a combined group (TEAS plus esketamine). TEAS will be applied to specific acupoints before delivery. Esketamine (0.15 mg/kg) will be administered intravenously immediately after the umbilical cord is clamped to minimize fetal exposure. The primary outcome is the overall quality of recovery, assessed using the ObsQoR-11 scale during the first three days after surgery. We will also evaluate pain levels, sleep quality, anxiety and depression, early recovery milestones, inflammatory responses, adverse reactions, and newborn safety. The results may provide an effective multi-modal strategy to enhance recovery for mothers after a cesarean delivery.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Background and Rationale:
Cesarean section is one of the most common obstetric surgeries globally. Inadequate postoperative pain management can negatively impact maternal sleep, early ambulation, breastfeeding, and increase the risk of postpartum anxiety and depression. Esketamine, an NMDA receptor antagonist, provides effective analgesia, opioid-sparing effects, and mood regulation. Transcutaneous electrical acupoint stimulation (TEAS) is a non-invasive neuromodulation technique that exerts analgesic effects through the endogenous opioid system and regulates gastrointestinal function. The clinical benefits of esketamine and TEAS are complementary, suggesting a potential synergistic effect in multimodal analgesia and enhanced recovery after surgery (ERAS).
Specific Study Design Rationale:
The acupoints selected in this trial (PC6, HT7, and LI4) are specifically targeted for their effects on pain relief, anxiolysis, and gastrointestinal motility. A disperse-dense frequency (2/10 Hz) is utilized to prevent nerve adaptation and maximize tolerance. Furthermore, to minimize fetal exposure, esketamine will be administered intravenously only after fetal delivery and umbilical cord clamping.
Significance:
This study aims to translate the theoretical synergistic benefits of these two interventions into clinical evidence. The findings will determine whether this combined strategy offers incremental benefits over single interventions in improving the overall quality of recovery for parturients, thereby providing a robust clinical basis for optimizing multimodal analgesic and ERAS protocols.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥ 18 years. (No upper age limit).
Primiparous women.
American Society of Anesthesiologists (ASA) physical status I or II.
Gestational age between 37 and 42 weeks.
Scheduled for elective cesarean section under epidural anesthesia.
Exclusion Criteria:
- History of allergy or contraindication to esketamine.
Contraindications to neuraxial anesthesia (e.g., coagulopathy).
Severe pregnancy complications (e.g., severe fetal distress, umbilical cord prolapse, placenta previa with massive hemorrhage, placental abruption).
Severe dysfunction of vital organs.
Skin breakdown or infection at the selected acupoint sites.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Control Group
Participants receive sham TEAS (device turned off) and an intravenous injection of 10 mL normal saline after umbilical cord clamping. |
10 mL of 0.9% normal saline administered intravenously as a placebo immediately after umbilical cord clamping. The TEAS device is applied to the same acupoints but with the electrical current turned off (the light flashes to blind the participant). |
|
Expérimental: TEAS Group
Participants receive active TEAS at PC6, HT7, and LI4 acupoints, and an intravenous injection of 10 mL normal saline after umbilical cord clamping. |
10 mL of 0.9% normal saline administered intravenously as a placebo immediately after umbilical cord clamping. Applied bilaterally at PC6 (Neiguan), HT7 (Shenmen), and LI4 (Hegu) acupoints using a Hwato DZ-III stimulator. Parameters: disperse-dense frequency of 2/10 Hz, intensity adjusted to the maximum tolerable level (6-12 mA). |
|
Expérimental: Esketamine Group
Participants receive sham TEAS and an intravenous injection of 0.15 mg/kg esketamine (diluted in 10 mL normal saline) after umbilical cord clamping. |
The TEAS device is applied to the same acupoints but with the electrical current turned off (the light flashes to blind the participant). Administered intravenously at a dose of 0.15 mg/kg (diluted in 10 mL normal saline) immediately after umbilical cord clamping. |
|
Expérimental: Combined Group
Participants receive active TEAS and an intravenous injection of 0.15 mg/kg esketamine (diluted in 10 mL normal saline) after umbilical cord clamping. |
Applied bilaterally at PC6 (Neiguan), HT7 (Shenmen), and LI4 (Hegu) acupoints using a Hwato DZ-III stimulator. Parameters: disperse-dense frequency of 2/10 Hz, intensity adjusted to the maximum tolerable level (6-12 mA). Administered intravenously at a dose of 0.15 mg/kg (diluted in 10 mL normal saline) immediately after umbilical cord clamping. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Quality of Postoperative Recovery
Délai: Postoperative days 1, 2, and 3.
|
Assessed using the ObsQoR-11 (Obstetric Quality of Recovery-11) scale. The score ranges from 0 to 110, with higher scores indicating better quality of recovery. |
Postoperative days 1, 2, and 3.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative Pain and Sedation
Délai: 12, 24, and 48 hours postoperatively (for VAS and PCA); perioperative period (for sedation).
|
Visual Analogue Scale (VAS) scores at rest and during movement (0 = no pain, 10 = worst pain); consumption and effective presses of patient-controlled analgesia (PCA); requirement for rescue analgesics (Flurbiprofen axetil); and Ramsay sedation scores. |
12, 24, and 48 hours postoperatively (for VAS and PCA); perioperative period (for sedation).
|
|
Sleep Quality and Psychological Status
Délai: 1 month preoperatively, postoperative days 1-2, and 1 month postoperatively.
|
Pittsburgh Sleep Quality Index (PSQI) for preoperative sleep; Leeds Sleep Evaluation Questionnaire (LSEQ) for postoperative sleep; Hospital Anxiety and Depression Scale (HADS); and Edinburgh Postnatal Depression Scale (EPDS). |
1 month preoperatively, postoperative days 1-2, and 1 month postoperatively.
|
|
Perioperative Hemodynamic Parameters
Délai: Baseline, after block reaches T6-S, skin incision, 1 and 5 minutes after study drug injection, fetal delivery, end of surgery, and 1 and 2 hours postoperatively.
|
Heart Rate (HR), Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and Mean Arterial Pressure (MAP). |
Baseline, after block reaches T6-S, skin incision, 1 and 5 minutes after study drug injection, fetal delivery, end of surgery, and 1 and 2 hours postoperatively.
|
|
Early Recovery Milestones and Perioperative Data
Délai: From surgery to hospital discharge.
|
Time to first flatus, first urination, first ambulation, and urinary catheter removal; length of hospital stay; surgical duration; intraoperative blood loss, urine output, and fluid infusion volume. |
From surgery to hospital discharge.
|
|
Inflammatory Markers
Délai: baseline and on postoperative day 2.
|
White Blood Cell (WBC) count, Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Lymphocyte Ratio (MLR). |
baseline and on postoperative day 2.
|
|
Maternal Adverse Events and Neonatal Outcomes
Délai: Intraoperative and postoperative days 1-3 (for maternal outcomes); immediately after delivery (for neonatal outcomes).
|
Incidence of maternal adverse reactions (e.g., nausea, vomiting, dizziness, hallucinations, skin allergies, respiratory depression); neonatal Apgar scores at 1 and 5 minutes; umbilical cord blood gas analysis (pH, Base Excess, lactate); and NICU admission rate. |
Intraoperative and postoperative days 1-3 (for maternal outcomes); immediately after delivery (for neonatal outcomes).
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Ciechanowicz S, Setty T, Robson E, Sathasivam C, Chazapis M, Dick J, Carvalho B, Sultan P. Development and evaluation of an obstetric quality-of-recovery score (ObsQoR-11) after elective Caesarean delivery. Br J Anaesth. 2019 Jan;122(1):69-78. doi: 10.1016/j.bja.2018.06.011. Epub 2018 Jul 31.
- Hung KC, Kao CL, Ho CN, Hsing CH, Chang YJ, Wang LK, Liao SW, Chen IW. The impact of perioperative ketamine or esketamine on the subjective quality of recovery after surgery: a meta-analysis of randomised controlled trials. Br J Anaesth. 2024 Jun;132(6):1293-1303. doi: 10.1016/j.bja.2024.03.012. Epub 2024 Apr 12.
- Zhou D, Hu B, He S, Li X, Gong H, Li F, Wang Q. Transcutaneous Electrical Acupoint Stimulation Accelerates the Recovery of Gastrointestinal Function after Cesarean Section: A Randomized Controlled Trial. Evid Based Complement Alternat Med. 2018 Nov 13;2018:7341920. doi: 10.1155/2018/7341920. eCollection 2018.
- Chen HZ, Gao Y, Li KK, An L, Yan J, Li H, Zhang J. Effect of intraoperative injection of esketamine on postoperative analgesia and postoperative rehabilitation after cesarean section. World J Clin Cases. 2024 Oct 6;12(28):6195-6203. doi: 10.12998/wjcc.v12.i28.6195.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2026KY498
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data will not be shared due to patient privacy and ethical restrictions. The data contains sensitive maternal and neonatal health information, and the informed consent obtained from participants does not permit public data sharing.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .